You are here: Home: Meet The Professors Vol. 3 Issue 4 2005: Case 1

Case 1: A 56-year-old woman with a 1.3-centimeter, high-grade, strongly ER/PRpositive, HER2-positive infiltrating ductal carcinoma with 6/15 positive nodes and extracapsular extension and an ejection fraction of 47 percent but an otherwise unremarkable cardiologic evaluation (from the practice of Dr Mansoor Javeed)
 

Perez EA et al. HER2 testing by local, central, and reference laboratories in the NCCTG N9831 Intergroup Adjuvant Trial. Proc ASCO 2004;Abstract 567.

Perez EA et al. NCCTG N9831: May 2005 update. Presentation. ASCO 2005; Abstract 556.

Piccart-Gebhart MJ. First results of the HERA trial. Presentation. ASCO 2005. No abstract available

Romond EH et al. Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER-2 positive operable breast cancer: Combined analysis of NSABP-B31/NCCTGN9831. Presentation. ASCO 2005. No abstract available

 

 

Table of Contents
 
Home · Contact Us
Terms of Use and General Disclaimer
Copyright © 2005 Research To Practice. All Rights Reserved